ABSTRACT:Different pharmacokinetic properties are known for the two enantiomers of the entactogen 3,4-methylendioxy-methamphetamine (MDMA), most likely due to enantioselective metabolism. The aim of the present work was 1) the investigation of the main sulfotransferases (SULT) isoenzymes involved in the sulfation of the main MDMA phase I metabolites 3,4-dihydroxymethamphetamine (DHMA) and 4-hydroxy-3-methoxymethamphetamine (HMMA) and 2) the evaluation of a possible enantioselectivity of this phase II metabolic step. Therefore, racemic DHMA and HMMA were incubated with heterologously expressed SULTs, and quantification of the sulfates by liquid chromatography-high-resolution mass spectrometry was conducted. Because separation of DHMA and HMMA sulfate could not be achieved by liquid chromatography, enantioselective kinetic parameters were determined using the substratedepletion approach with enantioselective quantification of substrate consumption by gas chromatography-negative ion chemical ionization mass spectrometry. SULT1A1 and SULT1A3 catalyzed sulfation of DHMA, and SULT1A3 and SULT1E1 catalyzed sulfation of HMMA. SULT1A1 and SULT1E1 revealed classic Michaelis-Menten kinetics, whereas SULT1A3 kinetics showed deviation from the typical Michaelis-Menten kinetics, resulting in a concentrationdependent self-inhibition. SULT1A3 showed the highest affinity and capacity of the SULT isoforms. Marked enantioselectivity could be observed for S-DHMA sulfation by SULT1A3 and in human liver cytosol, whereas no differences were observed for HMMA sulfation. Finally, comparison of K m and V max values calculated using achiral product formation and chiral substrate depletion showed good correlation within 2-fold of each other. In conclusion, preferences for S-enantiomers were observed for DHMA sulfation, but not for HMMA sulfation.
IntroductionThe chiral compound R, R,propane-2-amine], also known as ecstasy, is known as a very popular drug of abuse, but it is also associated with damage of serotonergic neurons (Kalant, 2001;Monks et al., 2004;Easton and Marsden, 2006). Metabolism of MDMA may play a role in this neurotoxicity (Miller et al., 1997;Bai et al., 1999;Mueller et al., 2009). As shown in Fig. 1, one major pathway of MDMA includes cytochrome P450 (P450)-catalyzed O-demethylation to 3,4-dihydroxymethamphetamine (DHMA), followed by O-methylation by catechol-O-methyltransferase (COMT) mainly to 4-hydroxy-3-methoxymethamphetamine (HMMA) and conjugation of DHMA and HMMA by sulfotransferases (SULTs) (Maurer, 1996;Maurer et al., 2000;. In urine samples of recreational MDMA users, more than 90% of DHMA and HMMA are excreted as conjugates, with sulfates present in higher concentrations (Shima et al., 2008; A. E. Schwaninger, M. R. Meyer, A. J. Barnes, E. A. Kolbrich-Spargo, D. A. Gorelick, R. S. Goodwin, M. A. Huestis, and H. H. Maurer, manuscript in preparation). For the two enantiomers of MDMA, differences in their dose-response curves and in their in vivo kinetics were observed (Fallon et al., 1999;Kalant, 2001;Kraemer a...